Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury

Ian A. Tamargo, Miaad Bader, Yazhou Li, Seong Jin Yu, Yun Wang, Konrad Talbot, Richard D. DiMarchi, Chaim G. Pick, Nigel H. Greig

Research output: Contribution to journalArticlepeer-review


Several single incretin receptor agonists that are approved for the treatment of type 2 diabetes mellitus (T2DM) have been shown to be neuroprotective in cell and animal models of neurodegeneration. Recently, a synthetic dual incretin receptor agonist, nicknamed “twincretin,” was shown to improve upon the metabolic benefits of single receptor agonists in mouse and monkey models of T2DM. In the current study, the neuroprotective effects of twincretin are probed in cell and mouse models of mild traumatic brain injury (mTBI), a prevalent cause of neurodegeneration in toddlers, teenagers and the elderly. Twincretin is herein shown to have activity at two different receptors, dose-dependently increase levels of intermediates in the neurotrophic CREB pathway and enhance viability of human neuroblastoma cells exposed to toxic concentrations of glutamate and hydrogen peroxide, insults mimicking the inflammatory conditions in the brain post-mTBI. Additionally, twincretin is shown to improve upon the neurotrophic effects of single incretin receptor agonists in these same cells. Finally, a clinically translatable dose of twincretin, when administered post-mTBI, is shown to fully restore the visual and spatial memory deficits induced by mTBI, as evaluated in a mouse model of weight drop close head injury. These results establish twincretin as a novel neuroprotective agent and suggest that it may improve upon the effects of the single incretin receptor agonists via dual agonism.

Original languageEnglish
Pages (from-to)176-186
Number of pages11
JournalExperimental Neurology
StatePublished - 1 Feb 2017


  • Glucagon-like peptide-1
  • Glucose-dependent insulinotropic peptide
  • Incretin
  • Incretin mimetic
  • Neurodegeneration
  • Traumatic brain injury


Dive into the research topics of 'Novel GLP-1R/GIPR co-agonist “twincretin” is neuroprotective in cell and rodent models of mild traumatic brain injury'. Together they form a unique fingerprint.

Cite this